Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,587 recruiting studies in this area right now.
By phase
- Not applicable9,776
- Phase 24,446
- Phase 12,737
- Phase 1/Phase 21,691
- Phase 31,394
- Phase 2/Phase 3280
- Phase 4263
Top conditions
- Breast Cancer1,226
- Cancer660
- Prostate Cancer651
- Colorectal Cancer494
- Lung Cancer425
- Ovarian Cancer340
- Multiple Myeloma332
- Gastric Cancer298
- Acute Myeloid Leukemia292
- Pancreatic Cancer292
- Hepatocellular Carcinoma283
- Solid Tumor256
- Advanced Solid Tumor255
- Cervical Cancer232
- Head and Neck Cancer226
- Endometrial Cancer206
- Advanced Solid Tumors192
- Bladder Cancer192
Leading sponsors
- M.D. Anderson Cancer Center451
- Fudan University312
- Sun Yat-sen University291
- Memorial Sloan Kettering Cancer Center289
- National Cancer Institute (NCI)287
- Mayo Clinic242
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center148
- AstraZeneca133
- University Health Network, Toronto125
Where studies are running
- California1,428
- Texas638
- Arizona513
- Florida448
- Alabama421
- New York407
- Massachusetts342
- Maryland329
- New Jersey267
- Pennsylvania245
Recruiting studies20,587 total
- NCT06058572RecruitingPhase 2
Rifaximin for gut bacteria after stem cell transplant in leukemia
This trial tests whether the antibiotic rifaximin can help protect the healthy bacteria in your gut after a stem cell transplant for acute leukemia. It may reduce infections and other complications during your recovery.
Navi Mumbai, MaharashtraAges 18–70 - NCT05917431RecruitingPhase 2
Radiation plus immunotherapy and targeted pills for liver cancer
This Phase 2 trial studies whether a combination of SBRT (focused radiation) plus tislelizumab and regorafenib can control unresectable or limited-spread liver cancer. It may help by attacking tumors in the liver and immune system to improve shrinkage and control of disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06042569RecruitingPhase 2
Lower-dose chemo for older women with HER2-negative breast cancer
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
Duarte, CaliforniaAges 65 years+ - NCT06027996Recruiting
Melodi Matrix in breast reconstruction
This trial tests a new mesh-like device called Melodi Matrix to support breast reconstruction after mastectomy. It may help women who are planning immediate two-stage implant reconstruction after removing one or both breasts.
Palo Alto, CaliforniaAges 22 years+ - NCT05940961RecruitingPhase 2
Inotuzumab for MRD-positive B-cell leukemia after transplant
This trial studies inotuzumab, a targeted cancer drug, for people whose B-cell ALL has returned at a very low level after a bone-marrow or stem-cell transplant. If you qualify, it may help push the leukemia back under control after transplant.
Suzhou, JiangsuAges 15–65 - NCT06134232RecruitingPhase 2
Extra sipuleucel-T after Provenge for prostate cancer
This trial tests whether adding one extra infusion of sipuleucel-T (the same drug as Provenge) after the standard three doses can help men with advanced prostate cancer that no longer responds to hormone therapy. It is for men who have already finished their three Provenge infusions and have mild or no symptoms.
Tuscon, ArizonaAges 18 years+ - NCT06121505RecruitingPhase 2
Low-dose radiation plus immunotherapy for advanced lung cancer
This trial tests whether adding low-dose radiation and a type of targeted radiation (SBRT) to a combination of immunotherapy (sintilimab) and chemotherapy works better than immunotherapy and chemotherapy alone for people with advanced squamous cell lung cancer.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06063018RecruitingPhase 2
Testing RC48 and Tislelizumab for recurrent cervical cancer with HER2
This trial tests a combination of two drugs, RC48 and Tislelizumab, for people with recurrent cervical cancer whose tumors have a protein called HER2. The goal is to see if this treatment can help when previous therapy has stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT05940441Recruiting
Low-dose capecitabine after throat cancer treatment
This study tests whether low-dose capecitabine given after standard treatment can lower the chance that locoregional (nearby) throat cancer returns. It is designed for adults with advanced hypopharyngeal (throat) cancer who have finished curative chemoradiation or surgery and follow-up therapy and show no active cancer on exam.
ShanghaiAges 18–65 - NCT06124976RecruitingPhase 2/Phase 3
A new treatment for low-grade kidney/ureter cancer (ST-02)
This trial tests a new treatment called ST-02 that is given directly into the kidney or ureter to destroy low-grade cancer cells without surgery. It may be an option for people whose cancer has not spread and who are looking for a less invasive treatment.
Vancouver, British ColumbiaAges 18 years+ - NCT05998278Recruiting
Personalized prostate biopsy study
This trial is testing a more personalized way to perform prostate biopsies. It's for men who have a suspicious finding on exam or imaging, or a higher PSA level, and who have had a special MRI that suggests cancer. The goal is to improve accuracy and reduce unnecessary biopsies.
Fuzhou, FujianAges 50–95 - NCT05929365Recruiting
Test genetic marker tracking to find returning colon polyps
This study looks at stool or tissue DNA changes (called mutation analysis) plus colonoscopy findings to detect whether colon polyps come back. It may help catch recurrent colorectal lesions earlier during surveillance after a large polyp was removed.
PragueAges 18–75 - NCT06022965Recruiting
Telemedicine support for older adults with cancer
This study uses telemedicine (video or phone visits) to help older adults with cancer, especially those in underserved communities, get better care. If you're 65 or older and starting a new cancer treatment, you may be able to join from home in English, Spanish, or Chinese.
Duarte, CaliforniaAges 65 years+ - NCT05830045RecruitingPhase 1
Testing a new drug for advanced solid tumors
This Phase 1 trial studies QLP2117, a new treatment, in people with advanced solid tumors that have come back or didn’t respond to standard care. It mainly looks at safety and how the body handles the drug, and it may help find a dose worth further study.
GuangzhouAges 18 years+ - NCT06031805Recruiting
Real-world study of olaparib for prostate cancer
This study looks at how men with advanced prostate cancer that has spread are doing while taking the drug olaparib. Researchers want to understand how well the drug works and what happens to patients over time.
AmiensAges 18 years+ - NCT06125041RecruitingPhase 2
Adebelizumab with chemo and radiation for advanced lung cancer
This trial tests a new drug called Adebelizumab (an immunotherapy) combined with chemotherapy and radiation for people with extensive stage small cell lung cancer. The goal is to see if this combination helps shrink tumors and improves survival.
Jinan, ShandongAges 18–75 - NCT06117540RecruitingPhase 2
WX390 for advanced solid tumors after standard treatment
This trial tests a new drug called WX390 for people whose advanced solid tumors have not responded to standard treatments. The study aims to see if WX390 can help shrink or slow the growth of these tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05718323RecruitingPhase 2
Niraparib with immunotherapy maintenance for advanced small-cell lung cancer
This trial tests whether adding niraparib (a pill cancer medicine) to ongoing immunotherapy maintenance can help people with advanced small-cell lung cancer live longer or better. It is for tumors that show a specific protein marker (SLFN11) and that did not worsen after standard first-line chemo-immunotherapy.
AngersAges 18 years+ - NCT06073626Recruiting
Genetic testing study for Black cancer survivors
This study offers free genetic testing to Black or African American people who have had certain cancers. It aims to find inherited gene changes that increase cancer risk and improve health equity.
Washington D.C., District of ColumbiaAges 18–80 - NCT05972655RecruitingPhase 2
Testing shorter rectal radiation with chemotherapy plus immunotherapy
This Phase 2 study tests whether a shorter course of radiation, combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab), can control middle and low rectal cancer. It may also help people who strongly want to keep their anus, if the cancer and overall health fit the study rules.
Hanzhou, ZhejiangAges 18–75 - NCT05884255RecruitingPhase 3
Lutetium brain-sparing therapy for advanced gut and pancreas tumors
This Phase 3 trial tests lutetium (Lu-177) oxodotreotide, a targeted treatment, for people with advanced gut and pancreas neuroendocrine tumors that are low or medium grade (G1 or G2). The study will see whether it helps control the cancer and symptoms in the right patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05852522Recruiting
Testing treatment planning to help eradicate rare advanced cancers
This trial looks at a more tailored way to choose treatment for people with rare cancers that have spread or grown locally and can’t be cured with standard therapies. The goal is to better target the tumor to improve the chance of tumor shrinkage or eradication.
HeidelbergAges 18 years+ - NCT05733689RecruitingPhase 1
Testing new pre-surgery treatment for stomach and esophagus cancer
This Phase 1 trial tests how well a tailored (response-adapted) chemotherapy plan works before surgery for stomach or gastroesophageal junction cancer. It aims to improve treatment planning while checking early safety.
Orange, CaliforniaAges 18 years+ - NCT05845801Recruiting
Study registry for young adults with pancreatic cancer
This study is a registry, meaning it collects information about young adults diagnosed with pancreatic cancer. It may help researchers better understand this cancer in younger people and improve future care.
VeronaAges 18–55
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,587 recruiting oncology studies from the U.S. registry right now, out of 31,171 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.